Scott Rocklage is the Managing Partner at 5AM Ventures. His educational background includes attending the University of California, Berkeley and earning a Bachelor of Science Degree in Chemistry.
Scott Rocklage received his Ph.D. in Chemistry from the Massachusetts Institute of Technology, also known as MIT. Scott Rocklage conducted research in Richard R. Schrock’s laboratory. Dr. Schrock received the Nobel Peace Prize in chemistry in 2005.
Scott Rocklage joined 5AM Ventures in 2003 when he became a Venture Partner at the company. He went on to become the Managing Partner of the company in 2004.
With more than three decades of healthcare management experience, Scott Rocklage has done important things in the industry, including getting FDA approval for the three medications known as Cubicin, Teslascan, and Omniscan. With more than 30 United States patents and more than 100 peer reviewed publications, Scott Rocklage has accomplished a lot.
Series A financing is the focus of Expansion Therapeutics, with the goal in mind of fighting genetic disorders. Myotonic Dystrophy type 1 is one of these genetic disorders that is being fought.
This genetic disorder is the leading cause of Muscular Dystrophy in adults, and so the company added $55.3 million to its coffers to fight this disease. Read more: Scott Rocklage | Bloomberg and Scott Rocklage | Crunchbase
When RNA reaches toxic levels, symptoms begin to show in the patients. Sanofi Ventures, Novartis Venture Fund, Kleiner Perkins and 5AM Ventures all wokred together to finance the project. Alexandria Venture Investments and RA Capital Management also took a stake in the financing of the project.